PA5-33691
antibody from Invitrogen Antibodies
Targeting: GPER1
CEPR, CMKRL2, DRY12, FEG-1, GPCR-Br, GPER, GPR30, LERGU, LERGU2, LyGPR
Antibody data
- Antibody Data
- Antigen structure
- References [1]
- Comments [0]
- Validations
- Immunohistochemistry [1]
- Other assay [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- PA5-33691 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- GPR30 Polyclonal Antibody
- Antibody type
- Polyclonal
- Antigen
- Synthetic peptide
- Description
- Percent identity with other species by BLAST analysis: Human, Gorilla (100%) Monkey, Marmoset (88%).
- Reactivity
- Human
- Host
- Rabbit
- Isotype
- IgG
- Vial size
- 50 µg
- Concentration
- 1 mg/mL
- Storage
- Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.
Submitted references Clinical candidate and genistein analogue AXP107-11 has chemoenhancing functions in pancreatic adenocarcinoma through G protein-coupled estrogen receptor signaling.
Mesmar F, Dai B, Ibrahim A, Hases L, Jafferali MH, Jose Augustine J, DiLorenzo S, Kang Y, Zhao Y, Wang J, Kim M, Lin CY, Berkenstam A, Fleming J, Williams C
Cancer medicine 2019 Dec;8(18):7705-7719
Cancer medicine 2019 Dec;8(18):7705-7719
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunohistochemical analysis of formalin-fixed paraffin-embedded human breast carcinoma using a GPR30 polyclonal antibody (Product # PA5-33691). Heat-induced antigen retrieval was performed prior to staining.
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 4 GPER1 as proposed molecular mechanism of genistein in pancreatic cancer cells. A, A higher expression of GPER1 mRNA (>68 RSEM) is correlated with better overall survival (log-rank test, P = .019) in the TCGA cohort of pancreatic cancer patients (n = 175). B, GPER1 mRNA and (C) protein is expressed in both MiaPaCa2 and PANC1, and higher in PANC1. Protein is indicated at approximately 43 kDa, the erythroleukemia HEL and leukemic monocyte THP1 cell lines that have no mRNA evidence of GPER1 (per the http://www.proteinatlas.org ) were used as negative controls, and GAPDH was used as a loading control. D, Proposed molecular mechanism of genistein includes activation of the GPER1 and downstream proposed targets, based on RNA-seq analysis of treated MiaPaCa2 and PANC1 cells. E, Expression (FPKM values) of proposed genistein-targets upregulated upon co-treatment with genistein compared to gemcitabine monotreatment (FDR < 0.05) in MiaPaCa2 (left) and PANC1 (right)